Literature DB >> 30322861

Lucy in the sky with ketamine: Psychoactive drugs have potential for a major breakthrough in treating depression.

Katrin Weigmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30322861      PMCID： PMC6216281          DOI： 10.15252/embr.201847118

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  10 in total

Review 1.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

2.  Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers.

Authors:  Vincent Bonhomme; Audrey Vanhaudenhuyse; Athena Demertzi; Marie-Aurélie Bruno; Oceane Jaquet; Mohamed Ali Bahri; Alain Plenevaux; Melanie Boly; Pierre Boveroux; Andrea Soddu; Jean François Brichant; Pierre Maquet; Steven Laureys
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

3.  Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment.

Authors:  Kathryn M Schak; Jennifer L Vande Voort; Emily K Johnson; Simon Kung; Jonathan G Leung; Keith G Rasmussen; Brian A Palmer; Mark A Frye
Journal:  Am J Psychiatry       Date:  2016-03-01       Impact factor: 18.112

Review 4.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

5.  Can a Framework Be Established for the Safe Use of Ketamine?

Authors:  Robert Freedman; Alan S Brown; Tyrone D Cannon; Benjamin G Druss; Felton J Earls; Javier Escobar; Yasmin L Hurd; David A Lewis; Carlos López-Jaramillo; Joan Luby; Helen S Mayberg; Terrie E Moffitt; Maria Oquendo; Roy H Perlis; Daniel S Pine; A John Rush; Carol A Tamminga; Mauricio Tohen; Eduard Vieta; Katherine L Wisner; Yu Xin
Journal:  Am J Psychiatry       Date:  2018-04-16       Impact factor: 18.112

6.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

Review 7.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Authors:  Gerard Sanacora; Mark A Frye; William McDonald; Sanjay J Mathew; Mason S Turner; Alan F Schatzberg; Paul Summergrad; Charles B Nemeroff
Journal:  JAMA Psychiatry       Date:  2017-04-01       Impact factor: 21.596

8.  Neural correlates of the LSD experience revealed by multimodal neuroimaging.

Authors:  Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 12.779

Review 9.  Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide.

Authors:  Ronald S Duman
Journal:  F1000Res       Date:  2018-05-24

10.  Psychedelics Promote Structural and Functional Neural Plasticity.

Authors:  Calvin Ly; Alexandra C Greb; Lindsay P Cameron; Jonathan M Wong; Eden V Barragan; Paige C Wilson; Kyle F Burbach; Sina Soltanzadeh Zarandi; Alexander Sood; Michael R Paddy; Whitney C Duim; Megan Y Dennis; A Kimberley McAllister; Kassandra M Ori-McKenney; John A Gray; David E Olson
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.